Endocision

What Endocision does

Endocision Technologies Inc. is a pre-commercial medical device company founded in 2019 and headquartered in Montreal, Quebec, that develops minimally invasive cryogenic catheters for lung disease diagnosis and therapy delivered through bronchoscopy and robotic bronchoscopy. Its lead product is a flexible cryobiopsy catheter that uses cryogenic freezing to sample lung tissue for histological analysis of interstitial lung disease, and that is designed to operate and be withdrawn independently from the bronchoscope, allowing safer transbronchial biopsies and multiple catheter insertions. The second product line is a novel detachable catheter system — the OTS platform, featured in the Journal of Thoracic and Cardiovascular Surgery Techniques — intended for precise transbronchial delivery of advanced therapeutic catheters and to extend the platform toward ablation and other lung therapies.

The company is targeting interventional pulmonologists and thoracic surgeons performing bronchoscopic procedures, in hospitals and medical centres using both conventional and robotic bronchoscopy. As of the available data, Endocision has not received FDA or other regulatory clearance, has no disclosed revenue or pricing, and is operating in a pre-commercial phase. It has built a peer-reviewed evidence base (JTCVS Techniques publication in 2022; participation in a human ex-vivo diseased lung clinical trial published in 2023), secured seed equity funding from Investissement Québec and private investors in February 2023, joined the MedTech Innovator 2023 accelerator cohort, and achieved ISO 13485:2016 and MDSAP certification in July 2024 — foundations it is leveraging to pursue regulatory clearance and an eventual direct-to-hospital field sales model.

Name

Endocision

Legal name

Endocision Technologies Inc.

Website

https://endocision.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Endocision is a pre-commercial Montreal-based medical device company developing minimally invasive cryogenic cryobiopsy catheters for lung disease diagnosis and therapy via conventional and robotic bronchoscopy, targeting interventional pulmonologists, thoracic surgeons and hospitals.

Ownership category

akta.pro rank

Product category

Interventional Pulmonology Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industry

Bronchoscopy & Interventional Pulmonology (HLAKANAJ)

Keywords

• Cryogenic medical devices
• Bronchoscopy catheters
• Interventional pulmonology
• Lung biopsy devices
• Robotic bronchoscopy accessories

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Endocision is developing cryogenic catheters for lung disease diagnosis and treatment. The company aims to commercialize its flexible cryobiopsy catheter for bronchoscopic interstitial lung disease biopsies in 2024. Revenue will come from selling medical devices to hospitals and healthcare providers.
2. Future Therapeutic Device Sales: The company is developing minimally invasive cryogenic devices for both diagnosis and treatment of lung diseases including interstitial lung disease and lung cancer. Future revenue may include therapeutic ablation catheters.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Endocision develops minimally invasive cryogenic catheters for lung disease diagnosis and therapy, with its lead product being a flexible cryobiopsy catheter that uses cryogenic freezing to collect lung tissue samples via bronchoscopy. The company also offers a detachable catheter system (OTS Platform) compatible with both standard and robotic bronchoscopy, enabling safer transbronchial ablation and multiple catheter insertions. Devices are intended for interventional pulmonologists and thoracic surgeons at hospitals and medical centers.

Product overview

Endocision is developing a portfolio of minimally invasive cryogenic devices for safer lung disease diagnosis and therapy. The primary products are the Flexible Cryobiopsy Catheter for bronchoscopic interstitial lung disease biopsies and the Detachable Catheter System (OTS Platform) for transbronchial catheter deployment. Both devices use proprietary cryogenic freezing technology to create precise and controlled lesions, and are designed to be compatible with standard bronchoscopy and robotic bronchoscopy techniques. The company is pursuing regulatory clearance and commercialization of these devices.

Differentiator

Problem solved

Functional benefit

Products and services

• Flexible Cryobiopsy Catheter A novel flexible cryobiopsy catheter using cryogenic freezing technology to collect anatomical lung tissue samples for histological analysis during bronchoscopic interstitial lung disease biopsies. Designed to be operated and withdrawn independently from the bronchoscope, intended for interventional pulmonologists and thoracic surgeons.
• Detachable Catheter System (OTS Platform) A novel detachable catheter system designed for transbronchial ablation of lung nodules, enabling precise catheter delivery that can be detached from the bronchoscope for procedural safety and multiple catheter insertions. Featured in the Journal of Thoracic and Cardiovascular Surgery (JTCVS) Techniques; compatible with both standard and robotic bronchoscopy.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• MedTech InnovatorcoreStrategic or Co-development Partner · 6 June 2023Endocision joined MedTech Innovator's 2023 accelerator program, one of the world's largest medtech programs, selected from over 1150 applicants. The company participates in conferences including Wilson Sonsini Medical Device Conference and AdvaMed MedTech conference.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Erbe Elektromedizin: German-based manufacturer of the Erbe cryoprobe, the established flexible cryocatheter for transbronchial cryobiopsy. Directly competes with Endocision in bronchoscopic lung tissue sampling with a similar cryogenic mechanism.
• IceCure Medical: Developer of cryoablation systems (ProSense platform) used across multiple indications including lung tumors. Competes with Endocision's planned therapeutic cryoablation catheter in the lung nodule ablation space.

Broad incumbents

• Boston Scientific: Diversified medtech with interventional pulmonology and ablation products (including legacy BTG cryo/thermal ablation assets). Competes broadly for hospital pulmonary and ablation budgets relevant to Endocision's expansion into lung therapy.
• Medtronic: Acquired CryoCath in 2008 and dominates the broader cryoablation space across cardiac and other indications. While Medtronic is not a direct cryobiopsy competitor today, its resources and prior CryoCath expertise (linked to Endocision's founder lineage) make it a potential strategic acquirer or competitor.
• Johnson & Johnson MedTech (Monarch): Owner of the Monarch robotic bronchoscopy platform (acquired via Auris Health). Competes in the same lung nodule biopsy and potential ablation workflow, representing both a potential integration partner and a competitive threat to Endocision's device.
• Olympus: Dominant bronchoscopy equipment manufacturer (scopes, processors, and accessories). Its installed base of bronchoscopes is the foundation on which Endocision's catheter is used, making Olympus both a critical ecosystem dependency and a potential competitor if it bundles or develops its own cryobiopsy catheter.
• Intuitive Surgical (Ion): Leader in robotic-assisted surgery, with the Ion robotic bronchoscopy platform competing for the same lung biopsy and ablation procedures Endocision targets. While Intuitive provides the platform rather than a biopsy catheter, the platform's bundled accessories compete for procedure share.
• Steris (US Endoscopy / Cool-tip): Through legacy US Endoscopy and cryotherapy product lines, Steris supplies cryosurgical and endoscopic tools used in pulmonary procedures. Competes broadly in the endoscopy and ablation tools market relevant to Endocision's platform.

Emerging players

• Noah Medical: Developer of the Galaxy System, a newer robotic bronchoscopy platform competing with Ion and Monarch. As a peer robotic platform, its installed base and accessory ecosystem could either complement or constrain Endocision's catheter opportunity.
• Body Vision Medical: Developer of AI-guided bronchoscopy tools (LungVision) for lung nodule diagnosis. Operates in the same bronchoscopic lung biopsy workflow as Endocision and represents an emerging complementary or competitive technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endocision

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endocision